J Neuroendocrinol. 2021 Oct 08;e13052. doi: 10.1111/jne.13052. Epub 2021 Oct 08.

The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.

Journal of neuroendocrinology

Pedro Marques, Sayka Barry, Eivind Carlsen, David Collier, Amy Ronaldson, Joan Grieve, Neil Dorward, Nigel Mendoza, Ramesh Nair, Samiul Muquit, Ashley B Grossman, Márta Korbonits

PMID: 34708902 DOI: 10.1111/jne.13052

Abstract

The neural cell adhesion molecule (NCAM) has previously been studied in pituitary neuroendocrine tumours (PitNETs), but its role in tumour biology and aggressiveness remains controversial, and its relationship with the tumour microenvironment remains unknown. We aimed to characterise NCAM expression in PitNETs, to correlate this with clinico-pathological features, and to assess the role of various microenvironment components on NCAM expression. NCAM and immune cells were investigated by immunohistochemistry in 16 human non-functioning-PitNETs (NF-PitNETs) and eight somatotrophinomas, including macrophages (CD68, CD163, HLA-DR), cytotoxic (CD8) and T helper (CD4) lymphocytes, regulatory T cells (FOXP3), B cells (CD20), and neutrophils (neutrophil elastase). Five normal pituitaries were included for comparison. The cytokine secretome from these PitNETs and from PitNET-derived tumour-associated fibroblasts (TAFs) were assessed on culture supernatants using a multiplex immunoassay panel. There were no significant NCAM expression differences between PitNETs and normal pituitary, and no difference between types of pituitary tumours (NF-PitNETs vs. somatotrophinomas). There was no association between NCAM expression and different clinico-pathological features, including cavernous sinus invasion and Ki-67, nor with serum hormone levels. NCAM immunoreactivity correlated negatively with PitNET-derived CXCL10 (rho = -0.417; p = .042) and CX3CL1 (rho = -0.423; p = .040) levels. NCAM immunoreactivity was negatively correlated with TAF-derived fibroblast growth factor (FGF)-2 (rho = -0.632; p = .009), but not with other TAF-derived cytokines. Within the PitNET cohort, there were no correlations between NCAM immunoreactivity and immune infiltrates or ratios, although, within NF-PitNETs, NCAM expression was higher in tumours with more FOXP3+ cells. NCAM expression does not differ between PitNETs and normal pituitary, and does not appear to relate to tumour invasiveness or proliferation. However, our data suggest a possible role for cytokines in the modulation of NCAM expression in PitNETs, particularly CXCL10, CX3CL1 and FGF-2, but not for immune cell infiltrates.

© 2021 British Society for Neuroendocrinology.

Keywords: neural cell adhesion molecule; pituitary adenoma; pituitary neuroendocrine tumour; tumour microenvironment

References

1. Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017;317(5):516-524. - PubMed
2. Kasuki L, Raverot G. Definition and diagnosis of aggressive pituitary tumors. Rev Endocr Metab Disord. 2020;21(2):203-208. - PubMed
3. Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C. How to classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers (Basel). 2020;12(2):514. - PubMed
4. Barbieri F, Bajetto A, Stumm R, et al. Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin Cancer Res. 2008;14(16):5022-5032. - PubMed
5. Mei YU, Bi WL, Greenwald NF, et al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016;7(47):76565-76576. - PubMed
6. Lupi I, Manetti L, Caturegli P, et al. Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma. J Clin Endocrinol Metab. 2010;95(1):289-296. - PubMed
7. Xing B, Kong YG, Yao Y, Lian W, Wang RZ, Ren ZY. Study on the expression levels of CXCR4, CXCL12, CD44, and CD147 and their potential correlation with invasive behaviors of pituitary adenomas. Biomed Environ Sci. 2013;26(7):592-598. - PubMed
8. Yoshida D, Koketshu K, Nomura R, Teramoto A. The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells. J Neurooncol. 2010;100(1):51-64. - PubMed
9. Marques P, Barry S, Carlsen E, et al. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Acta Neuropathol Commun. 2019;7(1):172. - PubMed
10. Marques P, Barry S, Carlsen E, et al. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. Endocr Relat Cancer. 2019;26(12):853-865. - PubMed
11. Weledji EP, Assob JC. The ubiquitous neural cell adhesion molecule (N-CAM). Ann Med Surg (Lond). 2014;3(3):77-81. - PubMed
12. Rubinek T, Yu R, Hadani M, et al. The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretion. J Clin Endocrinol Metab. 2003;88(8):3724-3730. - PubMed
13. Trouillas J, Daniel L, Guigard M-P, et al. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. J Neurosurg. 2003;98(5):1084-1093. - PubMed
14. Van Acker HH, Capsomidis A, Smits EL, Van Tendeloo VF. CD56 in the immune system: more than a marker for cytotoxicity? Front Immunol. 2017;8:892. - PubMed
15. Langley OK, Aletsee-Ufrecht MC, Grant NJ, Gratzl M. Expression of the neural cell adhesion molecule NCAM in endocrine cells. J Histochem Cytochem. 1989;37(6):781-791. - PubMed
16. Schmid R-S, Graff RD, Schaller MD, et al. NCAM stimulates the Ras-MAPK pathway and CREB phosphorylation in neuronal cells. J Neurobiol. 1999;38(4):542-558. - PubMed
17. Hinsby AM, Berezin V, Bock E. Molecular mechanisms of NCAM function. Front Biosci. 2004;9:2227-2244. - PubMed
18. Cavallaro U, Christofori G. Multitasking in tumor progression: signaling functions of cell adhesion molecules. Ann N Y Acad Sci. 2004;1014:58-66. - PubMed
19. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4(2):118-132. - PubMed
20. Raveh S, Gavert N, Ben-Ze'ev A. L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett. 2009;282(2):137-145. - PubMed
21. Daniel L, Bouvier C, Chetaille B, et al. Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior. Hum Pathol. 2003;34(6):528-532. - PubMed
22. Prag S, Lepekhin EA, Kolkova K, et al. NCAM regulates cell motility. J Cell Sci. 2002;115(Pt 2):283-292. - PubMed
23. Crnic I, Strittmatter K, Cavallaro U, et al. Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis. Cancer Res. 2004;64(23):8630-8638. - PubMed
24. Pyo JS, Kim DH, Yang J. Diagnostic value of CD56 immunohistochemistry in thyroid lesions. Int J Biol Markers. 2018;33(2):161-167. - PubMed
25. Berardi M, Hindelang C, Laurent-Huck FM, et al. Expression of neural cell adhesion molecules, NCAMs, and their polysialylated forms, PSA-NCAMs, in the developing rat pituitary gland. Cell Tissue Res. 1995;280(2):463-472. - PubMed
26. Aletsee-Ufrecht MC, Langley K, Gratzl O, Gratzl M. Differential expression of the neural cell adhesion molecule NCAM 140 in human pituitary tumors. FEBS Lett. 1990;272(1-2):45-49. - PubMed
27. Kleinschmidt-DeMasters BK, Conway DR, Franklin WA, Lillehei KO, Kruse CA. Neural cell adhesion molecule expression in human pituitary adenomas. J Neurooncol. 1995;25(3):205-213. - PubMed
28. De Jong I, Aylwin SJB, Olabiran Y, et al. Expression and secretion of neural cell adhesion molecules by human pituitary adenomas. Ann Clin Biochem. 1999;36(Pt 5):660-665. - PubMed
29. Daniel L, Trouillas J, Renaud W, et al. Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats) is related to growth rate and malignancy. Cancer Res. 2000;60(1):80-85. - PubMed
30. Mendes GA, Haag T, Trott G, et al. Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly. Braz J Med Biol Res. 2017;51(2):1-8. https://doi.org/10.1590/1414-431X20176808 - PubMed
31. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25(3):315-322. - PubMed
32. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549-555. - PubMed
33. Singhal S, Stadanlick J, Annunziata MJ, et al. Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci Transl Med. 2019;11(479):eaat1500. - PubMed
34. Troiano G, Caponio VCA, Adipietro I, et al. Prognostic significance of CD68(+) and CD163(+) tumor associated macrophages in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 2019;93:66-75. - PubMed
35. Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013;126(1):123-135. - PubMed
36. Melmed S. Pituitary tumors. Endocrinol Metab Clin North Am. 2015;44(1):1-9. - PubMed
37. Raverot G, Dantony E, Beauvy J, et al. Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab. 2017;102(9):3368-3374. - PubMed
38. Ongaratti BR, Haag T, D'Ávila MF, et al. Gene and protein expression of E-cadherin and NCAM markers in non-functioning pituitary adenomas. Ann Diagn Pathol. 2019;38:59-61. - PubMed
39. Ramsdell JS, Tashjian AH Jr. GH4 pituitary cell variants selected as nonresponsive to thyrotropin-releasing hormone-enhanced substratum adhesion are nonresponsive to epidermal growth factor: evidence for a common signaling defect. J Cell Physiol. 1989;141(3):565-572. - PubMed
40. Meager A. Cytokine regulation of cellular adhesion molecule expression in inflammation. Cytokine Growth Factor Rev. 1999;10(1):27-39. - PubMed
41. Harjunpaa H, Llort Asens M, Guenther C, Fagerholm SC. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front Immunol. 2019;10:1078. - PubMed
42. Chavarria A, Cardenas G. Neuronal influence behind the central nervous system regulation of the immune cells. Front Integr Neurosci. 2013;7:64. - PubMed
43. Suzumura A, Sawada M, Yamamoto H, Marunouchi T. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J Immunol. 1993;151(4):2150-2158. - PubMed
44. Balzarini P, Benetti A, Invernici G, et al. Transforming growth factor-beta1 induces microvascular abnormalities through a down-modulation of neural cell adhesion molecule in human hepatocellular carcinoma. Lab Invest. 2012;92(9):1297-1309. - PubMed
45. Cave DD, Di Guida M, Costa V, et al. TGF-beta1 secreted by pancreatic stellate cells promotes stemness and tumourigenicity in pancreatic cancer cells through L1CAM downregulation. Oncogene. 2020;39(21):4271-4285. - PubMed
46. Geertsen R, Zenklusen R, Kamarashev J, Burg G, Dummer R. Inverse regulation of neuronal cellular adhesion molecule (NCAM) by IFN-gamma in melanoma cell cultures established from CNS lesions. Int J Cancer. 1999;83(1):135-140. - PubMed
47. Janiszewska M, Primi MC, Izard T. Cell adhesion in cancer: beyond the migration of single cells. J Biol Chem. 2020;295(8):2495-2505. - PubMed
48. Downer EJ, Cowley TR, Lyons A, et al. A novel anti-inflammatory role of NCAM-derived mimetic peptide, FGL. Neurobiol Aging. 2010;31(1):118-128. - PubMed
49. Ray D, Melmed S. Pituitary cytokine and growth factor expression and action. Endocr Rev. 1997;18(2):206-228. - PubMed
50. Spoletini M, Taurone S, Tombolini M, et al. Trophic and neurotrophic factors in human pituitary adenomas (Review). Int J Oncol. 2017;51(4):1014-1024. - PubMed
51. Renner U, Paez-Pereda M, Arzt E, Stalla GK. Growth factors and cytokines: function and molecular regulation in pituitary adenomas. Front Horm Res. 2004;32:96-109. - PubMed
52. Ezzat S. The role of hormones, growth factors and their receptors in pituitary tumorigenesis. Brain Pathol. 2001;11(3):356-370. - PubMed
53. Ezzat S, Melmed S. The role of growth factors in the pituitary. J Endocrinol Invest. 1990;13(8):691-698. - PubMed
54. Missale C, Fiorentini C, Finardi A, Spano P. Growth factors in pituitary tumors. Pituitary. 1999;1(3-4):153-158. - PubMed
55. Saeger W. Expression of growth factors in normal and neoplastic pituitary tissues. Endocr Pathol. 2000;11(4):295-300. - PubMed
56. Spada A, Lania A. Growth factors and human pituitary adenomas. Mol Cell Endocrinol. 2002;197(1-2):63-68. - PubMed
57. Kiselyov VV, Soroka V, Berezin V, Bock E. Structural biology of NCAM homophilic binding and activation of FGFR. J Neurochem. 2005;94(5):1169-1179. - PubMed
58. Walmod PS, Kolkova K, Berezin V, Bock E. Zippers make signals: NCAM-mediated molecular interactions and signal transduction. Neurochem Res. 2004;29(11):2015-2035. - PubMed
59. Takase N, Koma Y-I, Urakawa N, et al. NCAM- and FGF-2-mediated FGFR1 signaling in the tumor microenvironment of esophageal cancer regulates the survival and migration of tumor-associated macrophages and cancer cells. Cancer Lett. 2016;380(1):47-58. - PubMed
60. Ditlevsen DK, Povlsen GK, Berezin V, Bock E. NCAM-induced intracellular signaling revisited. J Neurosci Res. 2008;86(4):727-743. - PubMed
61. Zecchini S, Bombardelli L, Decio A, et al. The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med. 2011;3(8):480-494. - PubMed
62. Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 1996;56(5):1111-1117. - PubMed
63. Akl MR, Nagpal P, Ayoub NM, et al. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 2016;7(28):44735-44762. - PubMed
64. Woodbury ME, Ikezu T. Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration. J Neuroimmune Pharmacol. 2014;9(2):92-101. - PubMed
65. Chae YK, Choi WM, Bae WH, et al. Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer. Sci Rep. 2018;8(1):1023. - PubMed
66. Crawford JM, Watanabe K. Cell adhesion molecules in inflammation and immunity: relevance to periodontal diseases. Crit Rev Oral Biol Med. 1994;5(2):91-123. - PubMed
67. Goridis C, Brunet JF. NCAM: structural diversity, function and regulation of expression. Semin Cell Biol. 1992;3(3):189-197. - PubMed
68. Ren G, Roberts AI, Shi Y. Adhesion molecules: key players in Mesenchymal stem cell-mediated immunosuppression. Cell Adh Migr. 2011;5(1):20-22. - PubMed
69. Rodrigues E, Macauley MS. Hypersialylation in cancer: modulation of inflammation and therapeutic opportunities. Cancers (Basel). 2018;10(6):207. - PubMed

Publication Types

• Journal Article

Grant support

• Medical Research Council (UK)
• Joan Adams Clinical Fellowship and the Barts and The London Charity Clinical Research Training Fellowship